Tremelimumab flopped, again, as monotherapy, this time with Astrazeneca plc. The drug failed to demonstrate effectiveness in overall survival (OS) compared to placebo in a randomized, double-blind phase IIb study in second- or third-line treatment of patients with unresectable pleural or peritoneal malignant mesothelioma.